Get the Stockscreener App
184.02
2.14%
-4.03
Pre-market:
184.26
0.24
+0.13%
Biogen Inc stock is traded at $184.02, with a volume of 1.05M.
It is down -2.14% in the last 24 hours and up +4.11% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$188.05
Open:
$185.01
24h Volume:
1.05M
Relative Volume:
0.61
Market Cap:
$27.01B
Revenue:
$9.53B
Net Income/Loss:
$1.29B
P/E Ratio:
20.90
EPS:
8.8057
Net Cash Flow:
$1.97B
1W Performance:
-5.69%
1M Performance:
+4.11%
6M Performance:
+29.94%
1Y Performance:
+29.86%
1-Day Range:
$181.79
$187.05
1-Week Range:
$181.79
$196.73
52-Week Range:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
184.02 | 27.60B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
1,007.73 | 909.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.75 | 599.00B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
233.86 | 414.21B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
164.18 | 318.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.76 | 315.94B | 58.80B | 10.24B | 8.98B | 3.2788 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
BIIB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management Reduces Biogen Stake - National Today
Biogen at TD Cowen Conference: Strategic Expansion and Challenges - Investing.com
Biogen Inc. (BIIB) Stock Analysis: Evaluating the 7.22% Upside Potential Amidst Market Dynamics - DirectorsTalk Interviews
Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry - TipRanks
TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Rafferty Asset Management LLC Lowers Stake in Biogen Inc. $BIIB - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Biogen (BIIB) Receives a Buy from RBC Capital - The Globe and Mail
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Fox Run Management L.L.C. Has $976,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Brokerages - MarketBeat
AMETHYST trial of litifilimab making "strong progress," Biogen says - Lupus News Today
Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says - marketscreener.com
Primecap Management Co. CA Has $2.09 Billion Stock Holdings in Biogen Inc. $BIIB - MarketBeat
10,006 Shares in Biogen Inc. $BIIB Acquired by K.J. Harrison & Partners Inc - MarketBeat
Dakota Wealth Management Acquires New Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Stock After Alzheimer’s Shake-Up: Bargain or Value Trap? - AD HOC NEWS
March 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen to Participate in the TD Cowen 46th Annual Health Care Conference - Biogen
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - AOL.com
Dementia Treatment Market Booming with Rapid Growth Through - openPR.com
Biogen Pharmachem Industries Ltd is Rated Strong Sell - Markets Mojo
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative - CSRwire
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative - CSRwire
Biogen Included in 2022 Bloomberg Gender-Equality Index - CSRwire
Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB - MarketBeat
Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
Beyond The Numbers: 21 Analysts Discuss Biogen Stock - Benzinga
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst - TipRanks
Barclays initiates Biogen stock coverage with $185 price target By Investing.com - Investing.com Nigeria
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra - GuruFocus
Barclays initiates Biogen stock coverage with $185 price target - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB - MarketBeat
New Biogen Chair Freire May Recast Partnerships And Capital Priorities - Yahoo Finance
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection - TradingView
Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Yahoo Finance
Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year - Yahoo Finance
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism - simplywall.st
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Therapeutics Market to Reach USD 46.22 - openPR.com
Aberdeen Group plc Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Biogen head of pharm ops Murphy buys $585 in stock By Investing.com - Investing.com Canada
Biogen head of pharm ops Murphy buys $585 in stock - Investing.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):